MinorDirect oral anticoagulants (factor Xa inhibitors)×Gabapentinoids (antiepileptics)
Updated · Methodology
Mechanism
Pregabalin undergoes negligible metabolism: less than 2% of a dose appears in the urine as metabolites and the rest is excreted unchanged by the kidneys. It does not bind to plasma proteins and does not inhibit drug metabolism in vitro. According to its SmPC, it is unlikely to cause or be subject to pharmacokinetic interactions (pregabalin SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). Apixaban has multiple elimination routes. It is metabolised mainly by CYP3A4/5, with minor contributions from other enzymes. Renal excretion accounts for about 27% of total clearance, and the rest leaves through bile and the intestine (apixaban SmPC, European Medicines Agency, EMA, section 5.2). Its exposure is changed by strong inhibitors and inducers of CYP3A4 and P-gp (apixaban SmPC, EMA, section 4.5), and pregabalin is not one of them.
Symptoms
The documents describe no symptoms caused by this combination. Pregabalin causes dizziness and somnolence, which can increase the risk of falls in older people. Loss of consciousness and confusion have been reported after marketing (pregabalin SmPC, European Medicines Agency, EMA, section 4.4). Apixaban increases the risk of bleeding. The most common adverse reactions are haemorrhage, contusion, epistaxis and haematoma (apixaban SmPC, EMA, sections 4.4 and 4.8).
Management
According to the documents, the combination is acceptable and no dose change of apixaban or pregabalin is needed. Neither document names the pair, and pregabalin does not alter the metabolism of other drugs (pregabalin and apixaban SmPCs, European Medicines Agency, EMA, section 4.5). People taking pregabalin are advised to be careful until they know how it affects them. In renal impairment, the pregabalin dose is reduced according to creatinine clearance (pregabalin SmPC, EMA, sections 4.2, 4.4 and 5.2). Apixaban is used with caution in conditions with an increased risk of bleeding and is stopped if severe haemorrhage occurs (apixaban SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5